AHA Coding Clinic® for HCPCS - 2013 Issue 3; For Your Information

Correct reporting of Rituximab and Bevacizumab - dosage vs. units

Rituximab and Bevacizumab are both chemotherapeutic drugs. Rituximab is utilized in the treatment of rheumatoid arthritis, Hodgkin’s lymphoma, and chronic lymphocytic leukemia. Bevacizumab is utilized in the treatment of patients with metastatic colorectal cancer. To accurately report the usage of Rituximab and Benvacizumab, billers and coders must verify the milligrams given and if necessary convert to the proper units, and ensure the quantity administered is consistent with the number of units billed. Key points to remember when billing Medicare for Rituximab: J9310 is defined in the HCPCS manual as: Injection, rituximab, 100 mg. One (1) unit represents 100...

To read the full article, sign in and subscribe to the AHA Coding Clinic® for HCPCS.


The AHA Coding Clinic for HCPCS includes:

  • The official publication for Level I HCPCS (CPT-4 codes) for hospital providers
  • Also specific Level II HCPCS codes for hospitals, physicians and other health professionals
  • Current newsletters added each quarter
  • Full Archives back to 2001
  • Fully searchable through Find-A-Code's Comprehensive Search
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information page link back to related articles
  • View all the articles associated with any code, right from the code page!
Access to this feature is available in the following products:
  • AHA's Coding Clinic® - HCPCS +Archives

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.